Cite
HARVARD Citation
Argnani, L. et al. (2022). Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy. HemaSphere. 6 (12), pp. e798-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Argnani, L. et al. (2022). Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy. HemaSphere. 6 (12), pp. e798-. [Online].